IL270357B2 - Lewy body disease therapeutic agent containing pyrazoloquinoline derivative - Google Patents
Lewy body disease therapeutic agent containing pyrazoloquinoline derivativeInfo
- Publication number
- IL270357B2 IL270357B2 IL270357A IL27035719A IL270357B2 IL 270357 B2 IL270357 B2 IL 270357B2 IL 270357 A IL270357 A IL 270357A IL 27035719 A IL27035719 A IL 27035719A IL 270357 B2 IL270357 B2 IL 270357B2
- Authority
- IL
- Israel
- Prior art keywords
- dementia
- rat
- disease
- test
- lewy body
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513727P | 2017-06-01 | 2017-06-01 | |
| PCT/JP2018/020650 WO2018221551A1 (ja) | 2017-06-01 | 2018-05-30 | ピラゾロキノリン誘導体を含有するレビー小体病治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL270357A IL270357A (https=) | 2020-02-27 |
| IL270357B1 IL270357B1 (en) | 2023-10-01 |
| IL270357B2 true IL270357B2 (en) | 2024-02-01 |
Family
ID=64456542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL270357A IL270357B2 (en) | 2017-06-01 | 2018-05-30 | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11311530B2 (https=) |
| EP (1) | EP3632438B1 (https=) |
| JP (1) | JP7269875B2 (https=) |
| KR (1) | KR20200010220A (https=) |
| CN (1) | CN110612102A (https=) |
| AU (1) | AU2018278422B2 (https=) |
| BR (1) | BR112019023552A2 (https=) |
| CA (1) | CA3061884A1 (https=) |
| ES (1) | ES2961554T3 (https=) |
| IL (1) | IL270357B2 (https=) |
| MX (1) | MX394435B (https=) |
| TW (1) | TWI784006B (https=) |
| WO (1) | WO2018221551A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018221550A1 (ja) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
| RU2019135834A (ru) | 2017-06-01 | 2021-07-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила |
| KR20200010211A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pde9 저해제를 포함하는 약제학적 조성물 |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100210839A1 (en) * | 2002-08-23 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes |
| EP2769980A1 (en) * | 2011-10-07 | 2014-08-27 | Eisai R&D Management Co., Ltd. | Pyrazoloquinoline derivative |
| EP2982675A1 (en) * | 2013-04-05 | 2016-02-10 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5318759A (en) | 1976-08-02 | 1978-02-21 | Nisshin Oil Mills Ltd | Method of making fried beancurd |
| JPH05132484A (ja) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | ピラゾロキノリン及びピラゾロナフチリジン誘導体 |
| DK0760819T3 (da) | 1994-05-24 | 2000-10-09 | Hoffmann La Roche | Tricykliske dicarbonylderivater |
| DE19642591A1 (de) | 1996-10-15 | 1998-04-16 | Basf Ag | Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| BR0313262A (pt) | 2002-08-07 | 2005-07-12 | Mitsubishi Pharma Corp | Compostos de dihidropirazolpiridina |
| DE102004004142A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine |
| RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| WO2005118583A1 (en) | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
| JP2006045118A (ja) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | 新規ピラゾロキノロン誘導体 |
| CA2622605A1 (en) | 2005-09-15 | 2007-03-22 | Aska Pharmaceutical Co., Ltd. | Heterocycle compound, and production process and application thereof |
| CA2671980C (en) | 2006-12-13 | 2015-05-05 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivatives |
| WO2008072778A1 (ja) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | 尿路系疾患の処置剤 |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| JP5453431B2 (ja) | 2008-09-08 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| WO2010101230A1 (ja) | 2009-03-05 | 2010-09-10 | アステラス製薬株式会社 | キノキサリン化合物 |
| PE20120505A1 (es) | 2009-03-31 | 2012-05-09 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| AP2012006631A0 (en) | 2010-08-12 | 2012-12-31 | Boehringer Ingelheim Int | 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors |
| RS54834B1 (sr) | 2010-09-07 | 2016-10-31 | Astellas Pharma Inc | Jedinjenja pirazolokvinolina |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| PT2573073E (pt) | 2011-09-26 | 2015-02-05 | Sanofi Sa | Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica |
| JP6042060B2 (ja) | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
| TW201439091A (zh) | 2013-04-05 | 2014-10-16 | Eisai R&D Man Co Ltd | 吡啶基吡唑并喹啉化合物 |
| KR20200010211A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pde9 저해제를 포함하는 약제학적 조성물 |
| RU2019135834A (ru) | 2017-06-01 | 2021-07-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила |
| WO2018221550A1 (ja) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
-
2018
- 2018-05-30 BR BR112019023552-3A patent/BR112019023552A2/pt not_active IP Right Cessation
- 2018-05-30 KR KR1020197033124A patent/KR20200010220A/ko not_active Ceased
- 2018-05-30 JP JP2019521251A patent/JP7269875B2/ja active Active
- 2018-05-30 TW TW107118423A patent/TWI784006B/zh active
- 2018-05-30 CN CN201880030146.7A patent/CN110612102A/zh active Pending
- 2018-05-30 WO PCT/JP2018/020650 patent/WO2018221551A1/ja not_active Ceased
- 2018-05-30 IL IL270357A patent/IL270357B2/en unknown
- 2018-05-30 EP EP18810202.4A patent/EP3632438B1/en active Active
- 2018-05-30 CA CA3061884A patent/CA3061884A1/en active Pending
- 2018-05-30 US US16/611,374 patent/US11311530B2/en active Active
- 2018-05-30 MX MX2019013397A patent/MX394435B/es unknown
- 2018-05-30 AU AU2018278422A patent/AU2018278422B2/en active Active
- 2018-05-30 ES ES18810202T patent/ES2961554T3/es active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100210839A1 (en) * | 2002-08-23 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes |
| EP2769980A1 (en) * | 2011-10-07 | 2014-08-27 | Eisai R&D Management Co., Ltd. | Pyrazoloquinoline derivative |
| EP2982675A1 (en) * | 2013-04-05 | 2016-02-10 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
Non-Patent Citations (1)
| Title |
|---|
| EISAI CO, LTD, MATERIALS IN REPORTER MEETING (NON-OFFICIAL TRANSLATION), 9 March 2017 (2017-03-09) * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2961554T3 (es) | 2024-03-12 |
| IL270357A (https=) | 2020-02-27 |
| BR112019023552A2 (pt) | 2020-06-02 |
| US11311530B2 (en) | 2022-04-26 |
| TW201902479A (zh) | 2019-01-16 |
| EP3632438B1 (en) | 2023-08-23 |
| JP7269875B2 (ja) | 2023-05-09 |
| AU2018278422B2 (en) | 2022-03-17 |
| MX394435B (es) | 2025-03-12 |
| RU2019135690A (ru) | 2021-07-13 |
| EP3632438A4 (en) | 2020-12-23 |
| MX2019013397A (es) | 2020-02-07 |
| AU2018278422A1 (en) | 2019-11-21 |
| WO2018221551A1 (ja) | 2018-12-06 |
| IL270357B1 (en) | 2023-10-01 |
| TWI784006B (zh) | 2022-11-21 |
| JPWO2018221551A1 (ja) | 2020-04-02 |
| CN110612102A (zh) | 2019-12-24 |
| KR20200010220A (ko) | 2020-01-30 |
| CA3061884A1 (en) | 2019-10-29 |
| RU2019135690A3 (https=) | 2021-08-25 |
| US20200155541A1 (en) | 2020-05-21 |
| EP3632438A1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nguyen et al. | Sigma-1 receptors and neurodegenerative diseases: towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection | |
| Qi et al. | NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo | |
| EP3632439B1 (en) | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil | |
| AU2018278422B2 (en) | Lewy body disease therapeutic agent containing pyrazoloquinoline derivative | |
| CA3217362A1 (en) | Mdma enantiomers | |
| KR102627790B1 (ko) | 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제 | |
| Anand et al. | The animal models of dementia and Alzheimer’s disease for pre-clinical testing and clinical translation | |
| EA037187B1 (ru) | Способ и композиция для лечения когнитивного расстройства | |
| Nandhu et al. | Opioid system functional regulation in neurological disease management | |
| Roger-Sánchez et al. | Neurochemical substrates of the rewarding effects of MDMA: implications for the development of pharmacotherapies to MDMA dependence | |
| RU2802212C2 (ru) | Терапевтическое средство для лечения болезни телец леви, содержащее производное пиразолохинолина | |
| WO2015060746A1 (ru) | Комбинация для лечения и/или профилактики проявлений психических, когнитивных, поведенческих и неврологических нарушений при органических заболеваниях цнс различного генеза | |
| Trobec et al. | Alzheimer's disease: etiological and risk factors, pathophysiological mechanisms and therapeutic approaches. | |
| Cromwell et al. | The role of the basal ganglia in the expression of stereotyped, self-injurious behaviors in developmental disorders | |
| Ohta et al. | Effects of NK-4, a cyanine dye with antioxidant activities: Attenuation of neuronal deficits in animal models of oxidative stress-mediated brain ischemia and neurodegenerative diseases | |
| Dineley | Nicotinic Acetylcholine Receptors in Alzheimer’s and Parkinson’s Disease | |
| Nguyen et al. | Shona Mookerjee, Nidhi Kaushal, and Rae R. Matsumoto | |
| JINLINGSUN et al. | Huperzine A inhibits immediate addictive behavior but not behavioral sensitization following repeated morphine administration in rats | |
| Sanjakdar | INVESTIGATING THE ROLE OF α6 and α4 CONTAINING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS IN NICOTINE AND COCAINE CONDITIONED PLACE PREFERENCE TESTS IN MICE. | |
| Cole | THE 9TH INTERNATIONAL CONFERENCE ON ALZHEIMER’S AND PARKINSON’S DISEASES (AD/PD) 2009 | |
| Kelly | Trends in Investigations of Parkinson's Disease |